Elizabeth G. Trehu
Plus aucun poste en cours
Profil
Elizabeth G.
Trehu held several positions in the pharmaceutical industry, including Vice President-Oncology Global Medical Affairs at Millennium Pharmaceuticals, Vice President & General Manager-Hematology at Genzyme Corp., and Chief Medical Officer at Promedior, Inc. She also served as an Independent Director at Constellation Pharmaceuticals, Inc. and is currently the Chief Medical Officer at Jounce Therapeutics, Inc. Trehu previously worked as an Assistant Professor at Tufts University School of Medicine.
She received her undergraduate degree from Princeton University and her doctorate from New York University School of Medicine.
Anciens postes connus de Elizabeth G. Trehu
| Sociétés | Poste | Fin |
|---|---|---|
| JOUNCE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/04/2023 |
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 15/07/2021 |
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Chief Tech/Sci/R&D Officer | 01/11/2015 |
| INFINITY PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2012 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2010 |
Formation de Elizabeth G. Trehu
| Princeton University | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Oncology
 Genzyme Oncology Pharmaceuticals: MajorHealth Technology Genzyme Oncology manufactures drugs for cancer therapies. Its products include Campath, B-CLL, and Colar which are used in the treatment of relapsed acute lymphoblastic leukemia in children. The company is headquartered in Cambridge, MA. | Health Technology |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Jounce Therapeutics, Inc.
 Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
